DIRAS1. a member of the Ras GTPase superfamily, is encoded by the DIRAS1 gene and shares structural homology with classical RAS proteins but exhibits distinct functional properties. Unlike oncogenic RAS isoforms, DIRAS1 is classified as a tumor suppressor due to its role in inhibiting cell proliferation, autophagy, and survival pathways. It is predominantly expressed in the brain, suggesting involvement in neurodevelopment and neurological disorders. DIRAS1 antibodies are immunological tools designed to detect and study the protein’s expression, localization, and interactions. These antibodies are critical for elucidating DIRAS1’s regulatory mechanisms, particularly its GTPase activity and downstream signaling in cancer, neurodegeneration (e.g., Alzheimer’s disease), and metabolic disorders. Commercial DIRAS1 antibodies are typically developed using immunogenic peptide regions and validated via Western blotting, immunohistochemistry, or immunofluorescence. Challenges include ensuring specificity due to homology with other RAS family members. Research utilizing DIRAS1 antibodies has highlighted its tumor-suppressive functions, such as downregulating PI3K/AKT/mTOR pathways, and its potential as a biomarker or therapeutic target. Ongoing studies aim to clarify its dual roles in autophagy and apoptosis, emphasizing its relevance in both cancer biology and neurological health.